Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.

BMC Ophthalmol · 2018 · PMC6288953 · PMID 30537942

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

3 a-c) show no significant LDH changes in regard to the cultivation time as well as any statistically significant differences among the study groups (ranibizumab (Lucentis®) versus bevacizumab (Avastin®)) There is only a slight trend independent from the antiangiogenic concentration that for bevacizumab (Avastin®) after 7 days and for ranibizumab (Lucentis®) after 3 days an increase in the LDH concentration could be observed.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.